NVO
The world is desperate for weight-loss drugs. But Big Pharma cant advertise them globally
Article Summary
HOLD- Novo Nordisk (NYSE: NOVO) is facing intense pressure from a global market for weight-loss drugs, but cannot advertise its GLP-1 medications Ozempic and Wegovy to the public due to strict UK advertising restrictions.
- Novo Nordisk ADR is banned from advertising prescription-only drugs to the general public, with only the US and New Zealand offering exceptions.
- The U.S. remains a major exception, where drug ad spending remains high due to First Amendment protections and relaxed regulations on TV and radio.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 16.8% | 25% | 60.0 ptsModerate (16.8%) - Decent growth |
| EPS Growth Next 5Y ? | -0.9% | 25% | 0.0 ptsNegative (-0.9%) - Declining expectations |
| Target Price Upside ? | 0.9% | 20% | 20.0 ptsMinimal Upside (0.9%) - Target: $49.81 vs Current: $49.37 |
| Gross Margin % ? | 81.8% | 15% | 100.0 ptsExceptional (81.8%) - Strong pricing power |
| Drawdown from 52-Wk High ? | -31.2% | 15% | 80.0 ptsSolid Dip (-31.2%) - Good entry zone |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About NVO
- Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
- It operates through two segments, Obesity and Diabetes Care, and Rare Disease.
- The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas.
- The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy.
- The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management.
- It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa.
- Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.